DeviceTalks Podcast Network - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

DeviceTalks Podcast Network — Technology
DeviceTalks Podcast Network

The DeviceTalks Podcast Network is the ultimate destination for all things #MedTech. By subscribing to this single feed, you’ll gain access to every podcast in our diverse and growing portfolio—more than a dozen unique shows featuring senior leaders, groundbreaking technology insights, and in-depth discussions on the most important topics in the medical device industry.

Each episode dives deep into critical areas like business strategy, market trends, surgical robotics, orthopedics, structural heart, neurology, and beyond. You’ll hear from leading voices at top companies—ranging from major OEMs to innovative startups—sharing their solutions, stories, and strategies for tackling the industry’s biggest challenges.

Our Lineup of Shows Includes:
• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neurovascular
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Enovis & Zimmer Biomet
• StrykerTalks

Why Subscribe?
Subscribing here means you’ll never miss an update from any of our shows. Whether you want a broad overview of the entire industry or prefer to tune into a specific series, this single feed has you covered.

If you discover a favorite topic, you can always subscribe to that individual show’s feed for a more tailored experience.

Meet Your Hosts:
• Tom Salemi, Editorial Director, DeviceTalks
• Kayleen Brown, Managing Editor, DeviceTalks

#DeviceTalks, Where Device Makers Connect.

Copyright: © All rights reserved

Latest Episodes:

Talking innovation with Johnson & Johnson's medtech R&D guru Martin Fitchet Dec 23, 2015

Show notes

Martin Fitchet is responsible for R&D at JNJ's medical device unit, a tall task for anyone but appropriate for this former surgeon. In this episode of DeviceTalks, we talk about what innovation means to a behemoth like JNJ and what areas he sees in medicine that are ripe for disruption.

A medtech veteran takes on C.diff: Rebiotix CEO Lee Jones Nov 18, 2015

Show notes

Clostridium difficile or C. diff. is a growing crisis in the U.S. with over 29,000 deaths and 500,000 cases annually, according to the CDC. The disease, which CDC officials warned can kill people in less than 30 days, is characterized by severe diarrhea, fever, and loss of appetite. Sadly, many elderly and infirmed patients are among the most vulnerable. Roseville, Minn.-based Rebiotix is one of a handful of companies looking to harness the human microbiome into a treatment for recurrent C. diff, which impacts about 20-30% of patients, where there are currently no approved drugs to treat patients with two or more recurrences. Rebiotix is currently in Phase 2 clinical trials for the treatment, which harnesses gut microbiota and turns them into therapies. The company hopes recurrent C. diff is just the 1st in a pipeline of treatments than can be derived from the microbiome. On this episode of DeviceTalks we discuss C.diff with Reviotix CEO Lee Jones. What personal stories led her to this mission; How powerful the human microbiome will be in the future of combating disease and the differences between running a medtech company and a biotech company.

The leadership lessons of Stryker's John Brown Nov 12, 2015

Show notes

For a man who took a private company from $17 million in sales to a $4.5 billion publicly traded juggernaut, John Brown is a remarkably humble man. However, he is, by all intents and purposes, the man who put Stryker on the map. Today, the Kalamazoo, Mich.-based medical device company nets nearly $10 billion in annual sales. In this episode of DeviceTalks, recorded at the recent AdvaMed 2015 conference, Brown spoke to us about how he built such impressive results during his tenure at Stryker, including the lessons he learned along the way.

Can Sirtex turn cancer into a chronic disease? Nov 12, 2015

Show notes

Big things sometimes come in small packages. For Sirtex Medical, the big thing comes in a really small package. The Australian medical device company’s flagship product - the SIR-sphere - is made up of 30 to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and flow into the liver where they kill tumors from the inside. In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson talks with Mangano about the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech companies to enter.

Building the Cologuard and the fight against colorectal cancer with Exact Sciences Graham Lidgard Oct 27, 2015

Show notes

Colon cancer is one of the most preventable cancers, yet it is also one of the deadliest forms of the disease. In this episode, we speak with Graham Lidgard, the Chief Science Officer, Senior Vice President of Research and Development at Exact Sciences, a Wisc. -based company that has developed a non invasive test to detect colorectal cancer without having to undergo a colonoscopy. We talk to Graham about the Cologuard test and his 40 year career developing breakthrough medical technology.

Exit interview: Stephen Ubl moves on from AdvaMed Oct 15, 2015

Show notes

Before Stephen Ubl departed for a job as the chief lobbyist for the pharmaceutical industry, medtech's main man in Washington D.C. sat down with us to reflect on his time as CEO of AdvaMed. In this episode of DeviceTalks, we go deep into Ubl's background, the fights over the medical device tax, forging a new partnership with the FDA and more.

Marie Johnson and the mission to prevent sudden heart attacks Oct 13, 2015

Show notes

Marie Johnson turned tragedy into a mission. In 2002, the CEO of Aum Cardiovascular lost her husband to a sudden heart attack, despite the fact that he was, by all accounts, a perfectly healthy man. Fast forward 13 years and her company has commercialized a non-invasive test designed to quickly detect significant coronary stenosis called the CADence. Johnson hopes the pre FDA-approved device, which is on the market in Germany, will eliminate needless death due to coronary artery disease. In this interview, recorded live at our DeviceTalks Minnesota event, touches on Johnson's incredible story.

One of medtech's most successful men reflects on failure Oct 13, 2015

Show notes

Dr. Manny Villafana is one of the most successful men in the history of medical innovation, having founded four companies, including CPI/Guidant Corp. and St. Jude Medical, Inc. His most recent venture, Kips Bay Medical was supposed to be his best work yet. However, problems with the FDA and shortfalls on funding doomed the company, which shut down in September 2015. Recorded live on September 23rd at DeviceTalks Minnesota, just one day after he resigned as CEO of Kips Bay Medical, we discuss failure with Dr. Villafana. How does someone who has had so much success deal with the opposite? What comes next for this serial entrepreneur?

The story behind Airing: One of medtech's most successful crowdfunding campaign Sep 25, 2015

Show notes

Stephen Marsh has more than 70 patents to his name but his most recent endeavor, the Airing device, may make him a household name. The Airing is a hoseless, maskless, disposable micro CPAP machine, which could one day change the game in sleep apnea. However, Marsh and company have already made quite the mark on medtech by running one of the most successful crowdfunding campaigns ever. The company has raised more than $1 million on Indiegogo, more than 10 times its initial goal. In this episode of DeviceTalks, we talk to Marsh about the Airing device, inventing technology that sticks and how the company pulled off such a successful crowd funding campaign.

Spinal cord injuries and the quest to find a better treatment with Invivo Therapeutics Mark Perrin Sep 14, 2015

Show notes

Ten years after it was spun out of MIT, Invivo Thereapeutics and its neuro scaffold treatment for traumatic spinal cord injuries is moving closer to a reality. The company has completed enrollment of its 5 patient pilot study, which has made headlines around the world and is looking to push forward on adding more patients. In this episode of DeviceTalks, we talk to new CEO Mark Perrin about the company and why there has been so little movement in the fight against paralysis.

Related Podcasts